Related Experiment Video
Updated: Apr 24, 2026

Lateral Chronic Cranial Window Preparation Enables In Vivo Observation Following Distal Middle Cerebral Artery Occlusion in Mice
Published on: December 29, 2016
[Neuroprotective treatment of chronic cerebrovascular insufficiency]
Insights
Cerebrolysin improved blood flow in patients with chronic brain ischemia by enhancing erythrocyte properties. This treatment positively impacts neurological and cognitive functions in these patients.
Area of Science:
- Neurology
- Hematology
Background:
- Chronic brain ischemia (CBI) affects neurological and cognitive functions.
- CBI is classified into stages I and II.
- Effective treatments for CBI are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of cerebrolysin in patients with chronic brain ischemia (CBI) stages I and II.
- To investigate the effects of cerebrolysin on neurological, emotional, and cognitive status.
- To assess cerebrolysin's impact on hemorheological parameters, including erythrocyte aggregation and deformity.
Main Methods:
- A study involving 300 patients with CBI, divided into stage I (195 patients) and stage II (105 patients).
- A control group of 45 patients did not receive cerebrolysin.
- Assessment included neurological and emotional status, cognitive functions, and hemorheological indicators (platelet and erythrocyte aggregation, deformity, morpho-densitometric parameters).
Main Results:
- Cerebrolysin administration led to improvements in neurological and emotional status.
- Cognitive functions showed positive changes following cerebrolysin treatment.
- The study identified enhanced morpho-densitometric characteristics of erythrocytes and improved hemorheological properties, crucial for capillary blood flow.
Conclusions:
- Cerebrolysin demonstrates efficacy in treating chronic brain ischemia stages I and II.
- The drug positively influences cognitive and neurological functions.
- Additional mechanisms of cerebrolysin action involve improving erythrocyte deformability and hemorheological parameters, vital for microcirculation.
Objective:
To study the efficacy of cerebrolysin in 300 patients with chronic brain ischemia (CBI), I and II stages.
Material And Methods:
The main group consisted of 195 patients with CBI, I stage and 105 patients with CBI, II stage. Patients of the control group (45 patients) did not receive cerebrolysin. Changes in neurological and emotional status, cognitive functions, indicators of platelet and erythrocyte aggregation, their deformity and morpho-densitometric parameters were studied.
Results And Conclusion:
Authors found the additional mechanisms of cerebrolysin action resulted in the improvement of morpho-densitometric characteristics of erythrocytes and hemorheological properties important for capillary blood flow.
More Related Videos
09:48Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
Published on: May 4, 2015
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction
Cerebral Edema ll: Pathophysiology